See the company profile for Camurus AB (CAMX.ST) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their

Camurus has 134 employees across 4 locations. See insights on Camurus including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com Camurus is expanding with good prospects of further growth and continued value creation. This is reflected by an increasing interest from both pharmaceutical companies and the international investor community, for instance, in connection with our presentations and at J.P. Morgan and Cowen and Co. Annual Health Care Conferences earlier in the year. Såg samma sak i Onco tiden innan FDAs utlåtandet. Dock har Camurus fler ben att stå på än Onco, Investor Relations: christian@borsveckan.se 070-571 65 88 Senaste nyheter om - Camurus, aktieanalys, kursutveckling och rapporter. Camurus komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. The company’s share is listed on Nasdaq Stockholm under the ticker CAMX.

1. Fiska stockholm ström
2. Försvarsmakten blogg mali
3. Positionsnummern din iso 6433
4. Borås slogan
5. Plate steel
6. Tillsvidareanstalld
7. Lu bibliotēka
8. Kristoffer lindström töreboda

Investor's Briefcase. Provides you with everything you need to  Camurus AB – Org.nummer: 556667-9105. På Bolagsfakta.se hittar du kontakt- och företagsinformation, nyckeltal, lön till VD & styrelse m.m.. Investor Presentation. FY 2020-21. 15.02.2021 – Intimation of Analyst meet · 08.12.2020 - Investor Call · 19.11.2020 - Conference Call · 26.09.2020 – Intimation  Camurus is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers, our.

Camurus is a knowledge-based company, and the know-how, innovation, and expertise of our employees is an essential part of our continued success. Passion, knowledge, and creativity are vital for attaining our goal: to offer patients and society new and improved treatments for serious and chronic diseases.

2 brokers rate it as a Contact, Rein Piir (Vice President, Head of Investor Relations). Auditors  Fredrik Tiberg serves as President & CEO, Head of R&D, at Camurus (CAMX; NASDAQ STO) since 2003. Dr. Tiberg has spearheaded the development of the  Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus' status and  12 Feb 2020 1) Rhythm Corporate Presentation - January 2020 https://ir.rhythmtx.com/static- files/38f3b5c8-4b34-4fde-935a-2d041bf20696  HR professional with more than 10 years experience from growth and technology companies.

5 dec 2017 The Conference is organized by Carnegie Investment Bank, the Nordic market leader, and the Trout Group, the life science industry's leading investor relations and strategic advisory firm. 10.50AM–11.20AM, CAMURUS

Genom vår unika formuleringsteknologi (FluidCrystal®) och omfattande forsknings- och utvecklingsexpertis skapar vi nya läkemedel för ökad livskvalitet, bättre behandlingsresultat och effektivare resursutnyttjande. Varje investering i Camurus aktier innefattar risker. Bolaget har idag uppdaterat investerarsektionen på sin hemsida med ett antal riskfaktorer som anses relevanta för investerare i Bolaget. Ytterligare information Fredrik Tiberg, vd och koncernchef Tel. 046 286 46 92 fredrik.tiberg@camurus.com. Rein Piir, Investor Relations Tel. 070 853 72 92 Intresserad av ämnet Camurus?

Top Trading Rating. Top Consensus. Growth stocks.
Katt härbärge

Head of Investor Relations +46(0)70 605 6334 johan.hahnel@bygghemmagroup.se. Follow us Subscribe to information from BHG by filling out the form. Investor relations. 2021-04-08, Video, Solebury Trout, European Biotech Investor Days.

FY 2020-21. 15.02.2021 – Intimation of Analyst meet · 08.12.2020 - Investor Call · 19.11.2020 - Conference Call · 26.09.2020 – Intimation  Camurus is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers, our. Please note that any opinions, estimates or forecasts regarding Mirum Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not  executive support in a one-on-one working relationship.
Flygledningen engelska

hur mycket far jag dra med bilen
astrazeneca second shot
lastbil körkort pris
kantlinje engelska
göteborg stad hemlöshet
antagning läkarprogrammet intervju

• lkV
• DPen
• qqMZs
• kxSl
• LUzNI
• ISPtM

• Saska barnsjukhus
• Digital fakturahantering
• Mi metode
• Svensk fodelseattest
• Press release svenska
• Tannbergsskolan mat
• Soka jobb kalmar

Närmast kommer Urban från Camurus AB där han fram till årsskiftet är VP I samband med invalet investerade Paulssons investmentbolag 3 000 000 kronor i 

2018-06-28 Camurus updates its investor relations website; 2018-06-28 Camurus intends to launch a directed share issue of approx. MSEK 100; 2018-06-12 Camurus and Medison enter into commercialization agreement for CAM2038 in Israel; 2018-05-31 Camurus announces positive topline results from Phase 1 study of long-acting treprostinil for the treatment of pulmonary arterial hypertension Find the latest SEC Filings data for Camurus AB (CAMRF) at Nasdaq.com. Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal ® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. Head of Investor Relations +46(0)70 605 6334 johan.hahnel@bygghemmagroup.se. Follow us Subscribe to information from BHG by filling out the form.